Tumor Biology

, Volume 37, Issue 2, pp 1693–1698 | Cite as

Association of the functional BCL-2 rs2279115 genetic variant and small cell lung cancer

  • Xinyu Yang
  • Feng Gao
  • Fei Ma
  • Yanli Ren
  • Hongwei Chen
  • Xue Liang
  • Sichong Han
  • Xiangyu Xiong
  • Wenting Pan
  • Changchun Zhou
  • Liqing Zhou
  • Ming Yang
Original Article

Abstract

As a well-known oncogene, B cell lymphoma-2 (BCL-2) can promote cancer cell survival through preventing their apoptosis. Several functional BCL-2 single nucleotide polymorphisms (SNPs), such as rs2279115, rs1801018, and rs1564483, have been identified and might contribute to cancer susceptibility. However, the involvement of these SNPs in small cell lung cancer (SCLC) was still unclear. As a result, we investigated associations between these three genetic variants and SCLC risk in a case-control design. Genotypes were determined in two independent case-control sets consisted of 520 SCLC patients and 1040 controls from two medical centers. Odds ratios (ORs) and 95 % confidence intervals (CIs) were calculated utilizing unconditional logistic regression. We found that only BCL-2 rs2279115 genetic variant significantly contributed to decreased SCLC risk in Chinese Han populations, with the rs2279115 A allele as the protective allele. Stratified analyses of association between BCL2 rs2279115 SNP and SCLC risk indicated that the functional polymorphism was only significantly associated with decreased risk of the limited stage SCLC but not the extensive stage disease. Our results indicate that the BCL-2 rs2279115 genetic variant was associated with SCLC risk in Chinese populations and support the hypothesis that SNPs in regulatory regions of oncogenes might contribute to cancer susceptibility.

Keywords

BCL-2 Polymorphism SCLC Susceptibility 

Notes

Funding supports

This study was financially supported by the National High-Tech Research and Development Program of China (2015AA020950), National Natural Science Foundation of China (31271382, 81201586), the Fundamental Research Funds for the Central Universities (YS1407), the open project of State Key Laboratory of Molecular Oncology (SKL-KF-2015-05), Beijing Higher Education Young Elite Teacher Project (YETP0521), and Innovation and Promotion Project of Beijing University of Chemical Technology.

Conflicts of interest

None

References

  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49.CrossRefPubMedGoogle Scholar
  2. 2.
    Jackman DM, Johnson BE. Small-cell lung cancer. Lancet. 2005;366(9494):1385–96.CrossRefPubMedGoogle Scholar
  3. 3.
    Simon GR, Wagner H. American College of Chest Physicians. Small cell lung cancer. Chest. 2003;123(1 Suppl):259S–71S.CrossRefPubMedGoogle Scholar
  4. 4.
    Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet. 2008;40(5):616–22.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008;452(7187):633–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008;452(7187):638–42.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Wang Y, Broderick P, Webb E, Wu X, Vijayakrishnan J, Matakidou A, et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet. 2008;40(12):1407–9.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    McKay JD, Hung RJ, Gaborieau V, Boffetta P, Chabrier A, Byrnes G, et al. Lung cancer susceptibility locus at 5p15.33. Nat Genet. 2008;40(12):1404–6.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Wang Y, McKay JD, Rafnar T, Wang Z, Timofeeva MN, Broderick P, et al. Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nat Genet. 2014;46(7):736–41.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Lan Q, Hsiung CA, Matsuo K, Hong YC, Seow A, Wang Z, et al. Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet. 2012;44(12):1330–5.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Dong J, Hu Z, Wu C, Guo H, Zhou B, Lv J, et al. Association analyses identify multiple new lung cancer susceptibility loci and their interactions with smoking in the Chinese population. Nat Genet. 2012;44(8):895–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Hu Z, Wu C, Shi Y, Guo H, Zhao X, Yin Z, et al. A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. Nat Genet. 2011;43(8):792–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Hockenbery D, Nuñez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990;348(6299):334–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004;116(2):205–19.CrossRefPubMedGoogle Scholar
  15. 15.
    Kelly PN, Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ. 2011;18(9):1414–24.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Higashiyama M, Doi O, Kodama K, Yokouchi H, Tateishi R. Bcl-2 oncoprotein expression is increased especially in the portion of small cell carcinoma within the combined type of small cell lung cancer. Tumour Biol. 1996;17(6):341–4.CrossRefPubMedGoogle Scholar
  17. 17.
    Pardo OE, Arcaro A, Salerno G, Raguz S, Downward J, Seckl MJ. Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis. J Biol Chem. 2002;277(14):12040–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Park BL, Kim LH, Cheong HS, Cho HY, Kim EM, Shin HD, et al. Identification of variants in cyclin D1 (CCND1) and B-cell CLL/lymphoma 2 (BCL2). J Hum Genet. 2004;49(8):449–54.CrossRefPubMedGoogle Scholar
  19. 19.
    Chen K, Hu Z, Wang LE, Sturgis EM, El-Naggar AK, Zhang W, et al. Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 2007;28(9):2008–12.CrossRefPubMedGoogle Scholar
  20. 20.
    Shi J, Sun F, Peng L, Li B, Liu L, Zhou C, et al. Leukocyte telomere length-related genetic variants in 1p34.2 and 14q21 loci contribute to the risk of esophageal squamous cell carcinoma. Int J Cancer. 2013;132(12):2799–807.CrossRefPubMedGoogle Scholar
  21. 21.
    Liu L, Zhou C, Zhou L, Peng L, Li D, Zhang X, et al. Functional FEN1 genetic variants contribute to risk of hepatocellular carcinoma, esophageal cancer, gastric cancer and colorectal cancer. Carcinogenesis. 2012;33(1):119–23.CrossRefPubMedGoogle Scholar
  22. 22.
    Zhang X, Zhou L, Fu G, Sun F, Shi J, Wei J, et al. The identification of an ESCC susceptibility SNP rs920778 that regulates the expression of lncRNA HOTAIR via a novel intronic enhancer. Carcinogenesis. 2014;35(9):2062–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Seto M, Jaeger U, Hockett RD, Graninger W, Bennett S, Goldman P, et al. Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J. 1988;7(1):123–31.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Young RL, Korsmeyer SJ. A negative regulatory element in the bcl-2 5′-untranslated region inhibits expression from an upstream promoter. Mol Cell Biol. 1993;13(6):3686–97.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Xu P, Liu L, Wang J, Zhang K, Hong X, Deng Q, et al. Genetic variation in BCL2 3′-UTR was associated with lung cancer risk and prognosis in male Chinese population. PLoS One. 2013;8(8), e72197.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Xinyu Yang
    • 1
  • Feng Gao
    • 2
  • Fei Ma
    • 3
  • Yanli Ren
    • 1
  • Hongwei Chen
    • 1
  • Xue Liang
    • 1
  • Sichong Han
    • 1
  • Xiangyu Xiong
    • 1
  • Wenting Pan
    • 1
  • Changchun Zhou
    • 4
  • Liqing Zhou
    • 5
  • Ming Yang
    • 1
  1. 1.State Key Laboratory of Chemical Resource Engineering, Beijing Laboratory of Biomedical Materials, College of Life Science and TechnologyBeijing University of Chemical TechnologyBeijingChina
  2. 2.Health Division of Guard Bureau, General Staff Department of Chinese PLABeijingChina
  3. 3.Department of Medical Oncology, Cancer HospitalChinese Academy of Medical SciencesBeijingChina
  4. 4.Clinical Laboratory, Shandong Cancer HospitalShandong Academy of Medical SciencesJinanChina
  5. 5.Department of Radiation OncologyHuaian No. 2 HospitalHuaianChina

Personalised recommendations